✦ LIBER ✦

Mitral insufficiency associated with primary antiphospholipid syndrome and chronic renal failure

✍ Scribed by Yasuyuki Kato; Fumitaka Isobe; Yasuyuki Sasaki; Kojiro Kodera; Hiroshi Kumano; Keima Nagamachi

Publisher: Springer Japan
Year: 2001
Tongue: Japanese
Weight: 188 KB
Volume: 49
Category: Article
ISSN: 1863-6705
DOI: 10.1007/bf02913596

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Secondary mitral valve replacement in an

Secondary mitral valve replacement in antiphospholipid syndrome and chronic renal failure

✍ Yasuyuki Kato; Fumitaka Isobe; Yasuyki Sasaki; Hiroshi Kumano; Keima Nagamachi; 📂 Article 📅 2001 🏛 Springer Japan 🌐 Japanese ⚖ 195 KB

A girl with Peters plus syndrome associa

A girl with Peters plus syndrome associated with myelomeningocele and chronic renal failure

✍ Osamu Motoyama; Hiroko Arai; Ryoko Harada; Kei Hasegawa; Kikuo Iitaka 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 177 KB

Purtscher-like retinopathy in nephrotic

Purtscher-like retinopathy in nephrotic syndrome associated with mild chronic renal failure

✍ D. Zwolińska; A. Medyńska; A. Galar; A. Turno 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 40 KB

Chronic renal failure and macrogenitalia

Chronic renal failure and macrogenitalia associated with genitourinary neurofibromatosis

✍ Bumin Nuri Dündar; Faruk Öktem; Abdullah Armağan; Nihal Olgaç Dündar; Sema Birca 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 112 KB

Bilateral vocal cord paralysis in a pati

Bilateral vocal cord paralysis in a patient with chronic renal failure associated with Alport syndrome

✍ Kazuhiro Watanabe; Keiichi Hagiya; Shinichi Inomata; Masayuki Miyabe; Makoto Tan 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 129 KB

Oral pharmacokinetics of pirenzepine in

Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis

✍ T. MacGregor; K. Matzek; J. Keirns; M. Vinocur; A. Chonko 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 215 KB

The pharmacokinetic properties of pirenzepine following administration of a single, 50 mg oral dose were evaluated in three groups of subjects: group I, end stage renal disease requiring maintenance haemodialysis (CLCR 0 to 10 ml.min-1); group II, moderate renal insufficiency (CLCR 10 to 30 ml.min-1